NAD+ dosing schedule
> Updated:
Calculate the NAD+ dose
The calculator is already set up for NAD+ — adjust the dose or diluent volume for your vial.
Human dosing
| Period / condition | Dose | Escalation |
|---|---|---|
| Start (tolerance) | 50 mg subcutaneously | Starting dose |
| Loading, 4–8 weeks | 50–100 mg, 2–3× weekly | Increase if tolerated |
| Maintenance | 100 mg, 1–2× weekly | Maximum in this schedule |
Practical dosing and effect details
The pharmacokinetics of NAD+ in humans were studied by Grant and colleagues (Frontiers in Aging Neuroscience, 2019): participants received a 6-hour intravenous infusion at 3 micromol per minute. The researchers found that NAD+ is cleared from plasma at almost the same rate it is infused: a measurable rise in urinary metabolites appeared only at the 6-hour mark, not right away. That fits the logic of the schedule on this page: instead of one large dose, the protocol starts at 50 mg to assess tolerance, then 50-100 mg 2-3x weekly across a 4-8 week loading phase, and 100 mg 1-2x weekly for maintenance, meaning regular smaller doses rather than an occasional large volume. Grant's study used an intravenous route, while the table above describes subcutaneous administration; these are two different routes, and a direct dose translation between them has not been established. This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
How to reconstitute
An example reconstitution for convenient dosing. The exact ratios depend on your vial. For research reference only — not medical guidance.
- 1Add the diluentUse bacteriostatic water. Example: 10 ml into a 1000 mg vial.NAD+1000 mg+ 10 mlDiluent
- 2Get the concentrationExample: 1000 mg in 10 ml =NAD+100 mg/ml(100,000 mcg/ml)
- 3Work out the volume per doseFor example, for a 50 mg dose:50 mg = 0.5 ml= 50 u. (U-100)
This is only an example calculation. You can use a different diluent volume — plug your own numbers into the calculator. Open calculator →
Research protocols
NAD+: reference regimens
A subcutaneous reference generalized from longevity-practice protocols; controlled clinical data on NAD+ are limited. Start at a lower dose to assess tolerance, then increase if needed.
NAD+ injection schedule in these protocols starts with a small dose to assess tolerance and then increases: NAD+'s short half-life in blood is why injections are given several times a week rather than once a month.
More scientific background in the NAD+ monograph
Notes and safety
- • NAD+ is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
